PDF(Pubmed)
Abstract：
UNASSIGNED: To study the efficacy of orbital injections of triamcinolone acetonide mixed 1:1 with dexamethasone in the treatment of active thyroid eye disease.
UNASSIGNED: Patients that received orbital injection(s) of triamcinolone acetonide mixed 1:1 with dexamethasone for thyroid eye disease were included in this retrospective study. Demographic and clinical data were collected from the pre-treatment and 1 month follow up evaluations. Clinical data included subjective pain and diplopia scores, best-corrected visual acuity, Intraocular pressure, extraocular motility, clinical activity score, Hertel exophthalmometry, and upper eyelid margin to reflex distance.
UNASSIGNED: Fifteen patients, 33 orbital injections, were included in the study. The average patient age was 59.2 years (SD ± 13.0) and 89% female. Subjectively, 67% of patients reported improvement of orbital pain and pressure versus 28% stable and 5% worse (p <0.001). Post-procedure clinical activity score decreased from 3.84 to 3.00 (p = 0.0004). There were no significant differences in upper eyelid margin to reflex distance (4.1 ± 1.4 mm vs. 4.3 ± 2.6 mm, p = 0.45), Hertel exophthalmometry (21.7 ± 9.4 mm vs. 21.8 ± 7.6 mm, p = 0.56), or extraocular motility (21% improved vs. 72% stable and 7% worsening, p = 0.50). No steroid-responsive increases in intraocular pressure or injection-related complications were reported.
UNASSIGNED: Orbital steroid injections can successfully reduce symptoms of TED and may be a reliable tool in the treatment of TED as a relatively safe, fast-acting, efficacious treatment option, particularly as a bridge to other therapies.
UNASSIGNED: Patients that received orbital injection(s) of triamcinolone acetonide mixed 1:1 with dexamethasone for thyroid eye disease were included in this retrospective study. Demographic and clinical data were collected from the pre-treatment and 1 month follow up evaluations. Clinical data included subjective pain and diplopia scores, best-corrected visual acuity, Intraocular pressure, extraocular motility, clinical activity score, Hertel exophthalmometry, and upper eyelid margin to reflex distance.
UNASSIGNED: Fifteen patients, 33 orbital injections, were included in the study. The average patient age was 59.2 years (SD ± 13.0) and 89% female. Subjectively, 67% of patients reported improvement of orbital pain and pressure versus 28% stable and 5% worse (p <0.001). Post-procedure clinical activity score decreased from 3.84 to 3.00 (p = 0.0004). There were no significant differences in upper eyelid margin to reflex distance (4.1 ± 1.4 mm vs. 4.3 ± 2.6 mm, p = 0.45), Hertel exophthalmometry (21.7 ± 9.4 mm vs. 21.8 ± 7.6 mm, p = 0.56), or extraocular motility (21% improved vs. 72% stable and 7% worsening, p = 0.50). No steroid-responsive increases in intraocular pressure or injection-related complications were reported.
UNASSIGNED: Orbital steroid injections can successfully reduce symptoms of TED and may be a reliable tool in the treatment of TED as a relatively safe, fast-acting, efficacious treatment option, particularly as a bridge to other therapies.
摘要：
■研究眼眶注射曲安奈德1：1混合地塞米松治疗活动性甲状腺眼病的疗效。
■接受曲安奈德1:1混合地塞米松眼眶注射治疗甲状腺眼病的患者被纳入本回顾性研究。从治疗前和1个月的随访评估中收集人口统计学和临床数据。临床数据包括主观疼痛和复视评分，最佳矫正视力，眼内压,眼外运动,临床活动评分，赫特尔眼球测量,和上眼睑边缘到反射距离。
■15名患者，33次眼眶注射，包括在研究中。患者平均年龄为59.2岁（SD±13.0），89％为女性。主观上,67%的患者报告眼眶疼痛和压力改善，28%稳定，5%恶化（p<0.001）。术后临床活动评分从3.84降至3.00(p=0.0004)。上眼睑边缘到反射距离没有显着差异（4.1±1.4mm与4.3±2.6mm,p=0.45),赫特尔眼球测量(21.7±9.4mmvs.21.8±7.6mm,p=0.56)，或眼外运动(21%改善vs.72%稳定，7%恶化，p=0.50)。未报告类固醇反应性眼内压升高或注射相关并发症。
■轨道类固醇注射可以成功地减轻TED的症状，并且可能是治疗TED的可靠工具，相对安全，快速行动，有效的治疗选择，尤其是作为其他疗法的桥梁。
■接受曲安奈德1:1混合地塞米松眼眶注射治疗甲状腺眼病的患者被纳入本回顾性研究。从治疗前和1个月的随访评估中收集人口统计学和临床数据。临床数据包括主观疼痛和复视评分，最佳矫正视力，眼内压,眼外运动,临床活动评分，赫特尔眼球测量,和上眼睑边缘到反射距离。
■15名患者，33次眼眶注射，包括在研究中。患者平均年龄为59.2岁（SD±13.0），89％为女性。主观上,67%的患者报告眼眶疼痛和压力改善，28%稳定，5%恶化（p<0.001）。术后临床活动评分从3.84降至3.00(p=0.0004)。上眼睑边缘到反射距离没有显着差异（4.1±1.4mm与4.3±2.6mm,p=0.45),赫特尔眼球测量(21.7±9.4mmvs.21.8±7.6mm,p=0.56)，或眼外运动(21%改善vs.72%稳定，7%恶化，p=0.50)。未报告类固醇反应性眼内压升高或注射相关并发症。
■轨道类固醇注射可以成功地减轻TED的症状，并且可能是治疗TED的可靠工具，相对安全，快速行动，有效的治疗选择，尤其是作为其他疗法的桥梁。
